ATE239752T1 - Pyrimidinderivate als markierte bindungspartner - Google Patents

Pyrimidinderivate als markierte bindungspartner

Info

Publication number: ATE239752T1
Authority: AT; Austria
Prior art keywords: sup; sub; ring; carbon atom; separated
Prior art date: 1993-09-17

Application number

AT94929830T

Other languages

English (en)

Inventor

Mark D Matteucci

Robert J Jones

Kuei-Ying Lin

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

1994-09-16

Publication date

2003-05-15

1994-09-16 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE239752T1 publication Critical patent/ATE239752T1/de

Links

CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
229910052799 carbon Inorganic materials 0.000 abstract 7
125000005842 heteroatom Chemical group 0.000 abstract 7
125000004432 carbon atom Chemical group C* 0.000 abstract 6
125000001072 heteroaryl group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000006413 ring segment Chemical group 0.000 abstract 2
108091034117 Oligonucleotide Proteins 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
239000001177 diphosphate Substances 0.000 abstract 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 1
235000011180 diphosphates Nutrition 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000004712 monophosphates Chemical class 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000001226 triphosphate Substances 0.000 abstract 1
235000011178 triphosphate Nutrition 0.000 abstract 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)
Indole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

AT94929830T 1993-09-17 1994-09-16 Pyrimidinderivate als markierte bindungspartner ATE239752T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/123,505 US5502177A (en)	1993-09-17	1993-09-17	Pyrimidine derivatives for labeled binding partners
PCT/US1994/010536 WO1995007918A2 (en)	1993-09-17	1994-09-16	Pyrimidine derivatives for labeled binding partners

Publications (1)

Publication Number	Publication Date
ATE239752T1 true ATE239752T1 (de)	2003-05-15

Family

ID=22409069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94929830T ATE239752T1 (de)	1993-09-17	1994-09-16	Pyrimidinderivate als markierte bindungspartner

Country Status (6)

Country	Link
US (5)	US5502177A (de)
EP (1)	EP0719272B1 (de)
JP (1)	JP4098356B2 (de)
AT (1)	ATE239752T1 (de)
DE (1)	DE69432636T2 (de)
WO (1)	WO1995007918A2 (de)

Families Citing this family (964)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US5433081A (en) *	1993-01-22	1995-07-18	Major; Thomas O.	Refrigerant recovery and purification method and apparatus with oil adsorbent separator
DE69433036T2 (de)	1993-09-03	2004-05-27	Isis Pharmaceuticals, Inc., Carlsbad	Aminoderivatisierte nukleoside und oligonukleoside
US5502177A (en) *	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
AU6996396A (en) *	1995-09-22	1997-04-09	Medical Research Council	Improvements in or relating to mutagenesis of nucleic acids
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
US20050053976A1 (en) *	1996-06-06	2005-03-10	Baker Brenda F.	Chimeric oligomeric compounds and their use in gene modulation
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US20050119470A1 (en) *	1996-06-06	2005-06-02	Muthiah Manoharan	Conjugated oligomeric compounds and their use in gene modulation
US20040203024A1 (en) *	1996-06-06	2004-10-14	Baker Brenda F.	Modified oligonucleotides for use in RNA interference
US7812149B2 (en) *	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040171031A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040033973A1 (en) *	2002-08-16	2004-02-19	Muthiah Manoharan	Compounds and oligomeric compounds comprising novel nucleobases
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US20040147022A1 (en) *	1996-06-06	2004-07-29	Baker Brenda F.	2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US6111085A (en)	1996-09-13	2000-08-29	Isis Pharmaceuticals, Inc.	Carbamate-derivatized nucleosides and oligonucleosides
USRE44779E1 (en)	1997-03-07	2014-02-25	Santaris Pharma A/S	Bicyclonucleoside and oligonucleotide analogues
US6617422B1 (en) *	1997-05-23	2003-09-09	Peter Nielsen	Peptide nucleic acid monomers and oligomers
EP1012331B1 (de)	1997-07-01	2006-03-29	Isis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US7572582B2 (en) *	1997-09-12	2009-08-11	Exiqon A/S	Oligonucleotide analogues
US6007992A (en) *	1997-11-10	1999-12-28	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US6028183A (en) *	1997-11-07	2000-02-22	Gilead Sciences, Inc.	Pyrimidine derivatives and oligonucleotides containing same
CA2309340C (en) *	1997-11-07	2006-02-21	Isis Pharmaceuticals Inc.	Pyrimidine derivatives for labeled binding partners
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US20040186071A1 (en) *	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
AU745880B2 (en) *	1998-05-21	2002-04-11	Isis Pharmaceuticals, Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
CA2329252A1 (en) *	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for topical delivery of oligonucleotides
EP1093373A4 (de) *	1998-07-02	2005-04-13	Univ Columbia	OLIGONUKLEOTIDE INHIBITOREN DES bcl-xl
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US20040081959A9 (en) *	1999-12-08	2004-04-29	Epoch Biosciences, Inc.	Fluorescent quenching detection reagents and methods
US6727356B1 (en) *	1999-12-08	2004-04-27	Epoch Pharmaceuticals, Inc.	Fluorescent quenching detection reagents and methods
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US20060166227A1 (en) *	2000-06-20	2006-07-27	Stephen Kingsmore	Protein expression profiling
US6323009B1 (en) *	2000-06-28	2001-11-27	Molecular Staging, Inc.	Multiply-primed amplification of nucleic acid sequences
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2001296846B2 (en)	2000-10-12	2007-07-05	University Of Rochester	Compositions that inhibit proliferation of cancer cells
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2004060278A2 (en)	2002-12-06	2004-07-22	Isis Pharmaceuticals, Inc.	Methods for rapid identification of pathogens in humans and animals
US7666588B2 (en) *	2001-03-02	2010-02-23	Ibis Biosciences, Inc.	Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7226739B2 (en)	2001-03-02	2007-06-05	Isis Pharmaceuticals, Inc	Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US7718354B2 (en) *	2001-03-02	2010-05-18	Ibis Biosciences, Inc.	Methods for rapid identification of pathogens in humans and animals
US20040121309A1 (en) *	2002-12-06	2004-06-24	Ecker David J.	Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US20030027135A1 (en)	2001-03-02	2003-02-06	Ecker David J.	Method for rapid detection and identification of bioagents
US20040121310A1 (en) *	2002-12-18	2004-06-24	Ecker David J.	Methods for rapid detection and identification of bioagents in forensic studies
US20040121314A1 (en) *	2002-12-06	2004-06-24	Ecker David J.	Methods for rapid detection and identification of bioagents in containers
DE60232785D1 (de)	2001-03-14	2009-08-13	Myriad Genetics Inc	Tsg101-gag-wechselwirkung und ihre verwendung
EP1992643A3 (de)	2001-06-20	2008-12-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
CA2451643C (en)	2001-06-21	2012-11-13	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US7217510B2 (en) *	2001-06-26	2007-05-15	Isis Pharmaceuticals, Inc.	Methods for providing bacterial bioagent characterizing information
US8073627B2 (en)	2001-06-26	2011-12-06	Ibis Biosciences, Inc.	System for indentification of pathogens
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
EP2143438B1 (de)	2001-09-18	2011-07-13	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US7070933B2 (en) *	2001-09-28	2006-07-04	Gen-Probe Incorporated	Inversion probes
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2002334895B2 (en)	2001-10-09	2006-10-19	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
US7553619B2 (en) *	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
AU2003269809A1 (en) *	2002-04-01	2003-12-12	Isis Pharmaceuticals, Inc.	Method for rapid detection and identification of viral bioagents
KR20040101502A (ko)	2002-04-16	2004-12-02	제넨테크, 인크.	종양의 진단 및 치료 방법 및 이를 위한 조성물
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
AU2003276131A1 (en) *	2002-06-18	2003-12-31	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
CA2495478A1 (en)	2002-08-05	2004-02-12	University Of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
AU2003275018B2 (en) *	2002-09-20	2009-10-01	Integrated Dna Technologies, Inc.	Anthraquinone quencher dyes, their methods of preparation and use
JP2006500030A (ja) *	2002-09-20	2006-01-05	イェールユニバーシティ	リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
EP1549767A4 (de)	2002-09-26	2006-06-07	Amgen Inc	Modulation der expression von forkhead-box o1a
JP2006515318A (ja) *	2002-10-29	2006-05-25	ファルマシア・コーポレーション	特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
WO2004044138A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003295387A1 (en) *	2002-11-05	2004-06-03	Isis Parmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
PT2336318E (pt)	2002-11-13	2013-06-12	Genzyme Corp	Modulação anti-sentido da expressão de apolipoproteína b
JP4986109B2 (ja)	2002-11-13	2012-07-25	ジェンザイム・コーポレーション	アポリポタンパク質ｂ発現のアンチセンス調節
DE60329526D1 (de) *	2002-11-15	2009-11-12	Morphotek Inc	Verfahren zur erzeugung einer hohen antikörperproduktion von durch in-vitro-immunisierung entstandenen hybridomen
CA2505601C (en)	2002-11-15	2014-10-28	Musc Foundation For Research Development	Complement receptor 2 targeted complement modulators
WO2004047749A2 (en)	2002-11-21	2004-06-10	University Of Utah Research Foundation	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US20040121312A1 (en) *	2002-12-18	2004-06-24	Ecker David J.	Methods for rapid detection and identification of the absence of bioagents
US20040121315A1 (en) *	2002-12-18	2004-06-24	Ecker David J.	Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in containers thereby
US20040122857A1 (en) *	2002-12-18	2004-06-24	Ecker David J.	Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in forensic studies thereby
US9487823B2 (en) *	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
AU2003299694A1 (en)	2002-12-20	2004-07-22	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
NZ541637A (en)	2003-02-11	2008-07-31	Antisense Therapeutics Pty Ltd	Modulation of insulin like growth factor I receptor
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US20040198640A1 (en) *	2003-04-02	2004-10-07	Dharmacon, Inc.	Stabilized polynucleotides for use in RNA interference
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US8046171B2 (en) *	2003-04-18	2011-10-25	Ibis Biosciences, Inc.	Methods and apparatus for genetic evaluation
US8057993B2 (en)	2003-04-26	2011-11-15	Ibis Biosciences, Inc.	Methods for identification of coronaviruses
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
US7964343B2 (en) *	2003-05-13	2011-06-21	Ibis Biosciences, Inc.	Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en)	2003-05-13	2012-04-17	Ibis Biosciences, Inc.	Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
EP1660512A4 (de) *	2003-06-02	2009-12-23	Isis Pharmaceuticals Inc	Oligonucleotid-synthese mit alternativen lösungsmitteln
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
EP1633770B1 (de)	2003-06-13	2015-04-29	Alnylam Europe AG	Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus
WO2005044976A2 (en) *	2003-06-20	2005-05-19	Isis Pharmaceuticals, Inc.	Oligomeric compounds for use in gene modulation
WO2005013901A2 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
AU2004268614C1 (en)	2003-08-27	2010-10-28	Ophthotech Corporation	Combination therapy for the treatment of ocular neovascular disorders
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20100035239A1 (en) *	2003-09-11	2010-02-11	Isis Pharmaceuticals, Inc.	Compositions for use in identification of bacteria
US8546082B2 (en)	2003-09-11	2013-10-01	Ibis Biosciences, Inc.	Methods for identification of sepsis-causing bacteria
US8288523B2 (en)	2003-09-11	2012-10-16	Ibis Biosciences, Inc.	Compositions for use in identification of bacteria
US20060240412A1 (en) *	2003-09-11	2006-10-26	Hall Thomas A	Compositions for use in identification of adenoviruses
US20080138808A1 (en) *	2003-09-11	2008-06-12	Hall Thomas A	Methods for identification of sepsis-causing bacteria
US8097416B2 (en)	2003-09-11	2012-01-17	Ibis Biosciences, Inc.	Methods for identification of sepsis-causing bacteria
NZ545134A (en)	2003-09-18	2009-06-26	Lilly Co Eli	Modulation of eIF4E expression
AU2004274021B2 (en) *	2003-09-18	2009-08-13	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
US7662929B2 (en)	2003-10-10	2010-02-16	Alchemia Oncology Pty Limited	Antibody that specifically binds hyaluronan synthase
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
US7439341B2 (en)	2003-11-14	2008-10-21	Integrated Dna Technologies, Inc.	Fluorescence quenching azo dyes, their methods of preparation and use
NZ596984A (en)	2003-11-17	2013-10-25	Genentech Inc	Compositions and methods for the treatment of tumor of hematopoietic origin
US20050164271A1 (en)	2004-01-20	2005-07-28	Sanjay Bhanot	Modulation of glucocorticoid receptor expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US20090280567A1 (en) *	2004-02-06	2009-11-12	Dharmacon, Inc.	Stabilized sirnas as transfection controls and silencing reagents
WO2005078094A2 (en) *	2004-02-06	2005-08-25	Dharmacon, Inc.	Stabilized rnas as transfection controls and silencing reagents
US7666592B2 (en) *	2004-02-18	2010-02-23	Ibis Biosciences, Inc.	Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en)	2004-03-03	2012-02-21	Ibis Biosciences, Inc.	Compositions for use in identification of alphaviruses
US8569474B2 (en) *	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2700720A3 (de)	2004-03-15	2015-01-28	Isis Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
KR101147147B1 (ko) *	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
EP3034510A1 (de)	2004-04-30	2016-06-22	Alnylam Pharmaceuticals Inc.	Oligonukleotide mit c5-modifiziertem pyrimidin
JP2008500064A (ja)	2004-05-21	2008-01-10	ザユーエービーリサーチファウンデーション	可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用
EP2458619B1 (de)	2004-05-24	2017-08-02	Ibis Biosciences, Inc.	Massenspektrometrie mit selektivem Ionfilter durch digitale Schwelle
US20050266411A1 (en) *	2004-05-25	2005-12-01	Hofstadler Steven A	Methods for rapid forensic analysis of mitochondrial DNA
US8394947B2 (en) *	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
CA2569419A1 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
EP1766052A4 (de) *	2004-06-03	2009-12-16	Isis Pharmaceuticals Inc	Chimärische oligomere zusammensetzungen mit gap
US7811753B2 (en)	2004-07-14	2010-10-12	Ibis Biosciences, Inc.	Methods for repairing degraded DNA
US7427675B2 (en)	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
WO2006135400A2 (en)	2004-08-24	2006-12-21	Isis Pharmaceuticals, Inc.	Methods for rapid identification of recombinant organisms
US7884086B2 (en) *	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
PL1809303T3 (pl)	2004-09-23	2019-11-29	Arc Medical Devices Inc	Kompozycje farmaceutyczne i sposoby dotyczące hamowania zrostów włóknistych lub stanów zapalnych przy użyciu fukanów o niskiej zawartości siarczanów
US7935811B2 (en) *	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
US7923206B2 (en) *	2004-11-22	2011-04-12	Dharmacon, Inc.	Method of determining a cellular response to a biological agent
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
US8182992B2 (en)	2005-03-03	2012-05-22	Ibis Biosciences, Inc.	Compositions for use in identification of adventitious viruses
US8084207B2 (en) *	2005-03-03	2011-12-27	Ibis Bioscience, Inc.	Compositions for use in identification of papillomavirus
US20060281680A1 (en)	2005-03-10	2006-12-14	Genentech, Inc.	Methods and compositions for modulating vascular integrity
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US20060223777A1 (en) *	2005-03-29	2006-10-05	Dharmacon, Inc.	Highly functional short hairpin RNA
US8309303B2 (en) *	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
WO2006127507A2 (en) *	2005-05-20	2006-11-30	Integrated Dna Technologies, Inc.	Compounds and methods for labeling oligonucleotides
WO2007008300A2 (en)	2005-05-31	2007-01-18	ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE	Triblock copolymers for cytoplasmic delivery of gene-based drugs
US8252756B2 (en)	2005-06-14	2012-08-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
EP1904655A2 (de) *	2005-07-21	2008-04-02	Isis Pharmaceuticals, Inc.	Verfahren zur raschen identifizierung und quantifizierung von nukleinsäurevarianten
CA2618665C (en)	2005-08-11	2012-11-13	J. Craig Venter Institute	Method for in vitro recombination
US20100015604A1 (en)	2005-08-17	2010-01-21	Evriklia Lianidou	Composition and method for determination of ck19 expression
JP5523705B2 (ja)	2005-08-29	2014-06-18	レグルス・セラピューティクス・インコーポレイテッド	Ｍｉｒ−１２２ａをモジュレートする使用方法
DE102005042073B4 (de) *	2005-08-31	2010-11-11	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Faserlaser
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
EP1941040A1 (de)	2005-09-19	2008-07-09	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	Modulation der expression des glucocorticoidrezeptors
ES2369328T3 (es)	2005-09-19	2011-11-29	Isis Pharmaceuticals, Inc.	Modulación de la expresión del receptor de glucagón.
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2392646A1 (de)	2005-10-14	2011-12-07	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
CN101365801B (zh)	2005-10-28	2013-03-27	阿尔尼拉姆医药品有限公司	抑制亨廷顿基因表达的组合物和方法
CA2626690A1 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
CA2630602A1 (en)	2005-11-21	2007-05-31	Isis Pharmaceuticals, Inc.	Modulation of eif4e-bp2 expression
EP1974052A2 (de) *	2005-12-21	2008-10-01	Yale University	Verfahren und zusammensetzungen in verbindung mit der modulation von riboschaltern
CN103301475B (zh)	2005-12-28	2016-08-03	斯克里普斯研究所	药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
JP5213723B2 (ja)	2006-01-27	2013-06-19	アイシスファーマシューティカルズ，インコーポレーテッド	マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
CA2640171C (en)	2006-01-27	2014-10-28	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
JP5704741B2 (ja)	2006-03-31	2015-04-22	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｅｇ５遺伝子発現の抑制のための組成物および方法
JP2009535383A (ja) *	2006-05-03	2009-10-01	バルティックテクロノジーデヴェロプメント，リミテッド	強く結合した塩基で修飾されたオリゴヌクレオチドと人工ヌクレアーゼを組み合わせたアンチセンス作用物質
DE102006020885A1 (de) *	2006-05-05	2007-11-08	Qiagen Gmbh	Einführung von Sequenzelementen in Nukleinsäuren
CA3044969A1 (en) *	2006-05-05	2007-12-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gene expression
JP5441688B2 (ja) *	2006-05-11	2014-03-12	アイシスファーマシューティカルズ，インコーポレーテッド	５’修飾二環式核酸類似体
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
JP2009537153A (ja)	2006-05-19	2009-10-29	アルニラムファーマシューティカルズ，インコーポレイテッド	ＡｈａのＲＮＡｉ調節およびその治療上の使用
AU2007253677B2 (en)	2006-05-22	2011-02-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of IKK-B gene
EP2023938A4 (de) *	2006-05-23	2010-11-10	Isis Pharmaceuticals Inc	Modulation von chrebp-expression
US9506056B2 (en) *	2006-06-08	2016-11-29	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
US20090280188A1 (en) *	2006-06-23	2009-11-12	Northwestern University	Asymmetric functionalizated nanoparticles and methods of use
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
EP2061799A4 (de) *	2006-09-11	2010-12-22	Univ Yale	Verfahren und zusammensetzungen zur verwendung von lysin-riboswitches
EP2064332B1 (de) *	2006-09-14	2012-07-18	Ibis Biosciences, Inc.	Gezielte gesamtgenomamplifizierung zur identifizierung von krankheitserregern
WO2008036841A2 (en) *	2006-09-22	2008-03-27	Dharmacon, Inc.	Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
US20100099858A1 (en) *	2006-09-28	2010-04-22	Mirkin Chad A	Maximizing Oligonucleotide Loading on Gold Nanoparticle
CA2665536C (en)	2006-10-05	2016-02-16	Massachusetts Institute Of Technology	Multifunctional encoded particles for high-throughput analysis
EP2104516B1 (de)	2006-11-01	2015-01-07	University of Rochester	Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
CN101600451A (zh)	2006-12-11	2009-12-09	犹他大学研究基金会	用于治疗病理性血管生成和血管通透性的组合物和方法
US20100129358A1 (en)	2006-12-22	2010-05-27	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
CA2691066C (en) *	2007-02-09	2018-07-31	Northwestern University	Particles for detecting intracellular targets
JP5680304B2 (ja) *	2007-02-23	2015-03-04	アイビスバイオサイエンシズインコーポレイティッド	迅速な法医学的ｄｎａ分析法
MX2009010081A (es)	2007-03-22	2010-01-20	Univ Yale	Metodos y composiciones relacionadas con los ribointerruptores (riboswitches) que controlan el corte y empalme (splicing) alternativo.
US20100204266A1 (en) *	2007-03-23	2010-08-12	Ibis Biosciences, INC	Compositions for use in identification of mixed populations of bioagents
AP3018A (en)	2007-03-29	2014-10-31	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expressionof a gene from the ebola
US20100221821A1 (en) *	2007-05-29	2010-09-02	Yale University	Methods and compositions related to riboswitches that control alternative splicing and rna processing
SG174103A1 (en)	2007-05-29	2011-09-29	Univ Yale	Riboswitches and methods and compositions for use of and with riboswitches
EP2170917B1 (de)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
US9598724B2 (en)	2007-06-01	2017-03-21	Ibis Biosciences, Inc.	Methods and compositions for multiple displacement amplification of nucleic acids
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
ES2386492T3 (es)	2007-06-08	2012-08-21	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos carbocíclicos
CN101796062B (zh) *	2007-07-05	2014-07-30	Isis制药公司	6-双取代双环核酸类似物
JP5572090B2 (ja) *	2007-08-15	2014-08-13	アイシスファーマシューティカルズ，インコーポレーテッド	テトラヒドロピラン核酸類似体
US8557767B2 (en)	2007-08-28	2013-10-15	Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) *	2007-08-28	2015-03-19	The Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en) *	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
CA2704560A1 (en) *	2007-11-05	2009-05-14	Baltic Technology Development, Ltd.	Use of oligonucleotides with modified bases in hybridization of nucleic acids
US8916531B2 (en) *	2007-11-20	2014-12-23	Isis Pharmaceuticals, Inc.	Modulation of CD40 expression
EP2617828B1 (de)	2007-12-10	2014-09-24	Alnylam Pharmaceuticals Inc.	Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
US7845686B2 (en) *	2007-12-17	2010-12-07	S & B Technical Products, Inc.	Restrained pipe joining system for plastic pipe
EP2224912B1 (de)	2008-01-02	2016-05-11	TEKMIRA Pharmaceuticals Corporation	Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
EP2265627A2 (de) *	2008-02-07	2010-12-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexitolnukleinsäureanaloga
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
US10131904B2 (en)	2008-02-11	2018-11-20	Rxi Pharmaceuticals Corporation	Modified RNAi polynucleotides and uses thereof
MX2010009611A (es)	2008-03-05	2010-12-15	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion de genes eg5 y vegf.
US8426378B2 (en)	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
WO2009124238A1 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
EP2274423A2 (de)	2008-04-04	2011-01-19	Isis Pharmaceuticals, Inc.	Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
ES2686708T3 (es)	2008-04-18	2018-10-19	Baxter International Inc.	Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
WO2009134917A2 (en) *	2008-04-29	2009-11-05	Wyeth	Methods for treating inflammation
US8815818B2 (en)	2008-07-18	2014-08-26	Rxi Pharmaceuticals Corporation	Phagocytic cell delivery of RNAI
US20110237646A1 (en) *	2008-08-07	2011-09-29	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression for the treatment of cns related disorders
DK2331141T3 (en)	2008-08-25	2016-04-04	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
US8318693B2 (en)	2008-09-02	2012-11-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mutant EGFR gene
WO2010033625A1 (en)	2008-09-16	2010-03-25	Ibis Biosciences, Inc.	Microplate handling systems and related computer program products and methods
EP2347254A2 (de)	2008-09-16	2011-07-27	Ibis Biosciences, Inc.	Probenverarbeitungseinheiten, -systeme und damit verbundene verfahren
WO2010033599A2 (en)	2008-09-16	2010-03-25	Ibis Biosciences, Inc.	Mixing cartridges, mixing stations, and related kits, systems, and methods
US8796443B2 (en)	2008-09-22	2014-08-05	Rxi Pharmaceuticals Corporation	Reduced size self-delivering RNAi compounds
DK2361256T3 (da)	2008-09-24	2013-07-01	Isis Pharmaceuticals Inc	Cyclohexenyl-nukleinsyreanaloger
DK2356129T3 (da) *	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
EP2334793B1 (de)	2008-09-25	2016-04-06	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
JP5777519B2 (ja)	2008-10-09	2015-09-09	テクミラファーマシューティカルズコーポレイション	改良されたアミノ脂質および核酸の送達方法
HRP20171969T1 (hr)	2008-10-15	2018-04-06	Ionis Pharmaceuticals, Inc.	Modulacija ekspresije faktora 11
SG10201809460SA (en)	2008-10-20	2018-11-29	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of transthyretin
AU2009308217B2 (en)	2008-10-24	2016-01-21	Ionis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
US8987435B2 (en)	2008-10-24	2015-03-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
CN102281872A (zh)	2008-11-24	2011-12-14	西北大学	多价rna纳米颗粒组合物
US9394333B2 (en)	2008-12-02	2016-07-19	Wave Life Sciences Japan	Method for the synthesis of phosphorus atom modified nucleic acids
CN108042560A (zh)	2008-12-04	2018-05-18	库尔纳公司	通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
KR101866152B1 (ko)	2008-12-04	2018-06-08	큐알엔에이, 인크.	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CA2746514C (en)	2008-12-10	2018-11-27	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
JP2012512665A (ja) *	2008-12-19	2012-06-07	アボット・ラボラトリーズ	ヒトｋ−ｒａｓのコドン１２−１３における突然変異の診断試験
WO2010080616A1 (en)	2008-12-19	2010-07-15	Abbott Laboratories	Molecular assay for diagnosis of malaria
US9493774B2 (en)	2009-01-05	2016-11-15	Rxi Pharmaceuticals Corporation	Inhibition of PCSK9 through RNAi
CA2749536A1 (en) *	2009-01-08	2010-07-15	Northwestern University	Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
CA2750820A1 (en)	2009-01-27	2010-08-05	Qiagen Gaithersburg	Thermophilic helicase dependent amplification technology with endpoint homogenous fluorescent detection
US20120101148A1 (en)	2009-01-29	2012-04-26	Alnylam Pharmaceuticals, Inc.	lipid formulation
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
ES2658626T3 (es)	2009-02-12	2018-03-12	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
EP2396803A4 (de)	2009-02-12	2016-10-26	Ibis Biosciences Inc	Ionisationssondenanordnungen
KR101682735B1 (ko)	2009-02-12	2016-12-06	큐알엔에이, 인크.	뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
EP2403946A4 (de)	2009-03-04	2012-11-14		Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
NZ594995A (en)	2009-03-12	2013-06-28	Alnylam Pharmaceuticals Inc	LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
MX2011009751A (es)	2009-03-16	2011-09-29	Opko Curna Llc	Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
JP5904935B2 (ja)	2009-03-17	2016-04-20	クルナ・インコーポレーテッド	デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
WO2010114842A1 (en)	2009-03-30	2010-10-07	Ibis Biosciences, Inc.	Bioagent detection systems, devices, and methods
CN102449170A (zh)	2009-04-15	2012-05-09	西北大学	寡核苷酸功能化的纳米颗粒的递送
EP3524275A1 (de)	2009-04-22	2019-08-14	Massachusetts Institute Of Technology	Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
CA2760589C (en)	2009-05-01	2019-08-20	Joseph Collard	Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
CA2760776C (en)	2009-05-05	2019-07-09	Alnylam Pharmaceuticals, Inc.	Lipid compositions for the delivery of therapeutic agents
CA3045126A1 (en)	2009-05-05	2010-11-11	Arbutus Biopharma Corporation	Methods of delivering oligonucleotides to immune cells
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
JP6250930B2 (ja)	2009-05-06	2017-12-20	クルナ・インコーポレーテッド	トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
US20120107331A1 (en)	2009-05-15	2012-05-03	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
JP5922017B2 (ja)	2009-05-18	2016-05-24	クルナ・インコーポレーテッド	リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療
EP2432882B1 (de)	2009-05-22	2019-12-25	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
WO2010138806A2 (en)	2009-05-28	2010-12-02	Curna, Inc.	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CA2764609C (en)	2009-06-10	2018-10-02	Alnylam Pharmaceuticals, Inc.	Improved cationic lipid of formula i
JP5944311B2 (ja)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
JP6128846B2 (ja)	2009-06-16	2017-05-17	クルナ・インコーポレーテッド	パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
EP2446036B1 (de)	2009-06-24	2017-03-01	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit tumornekrose faktor-rezeptor 2 (tnfr2) mittels hemmung des natürlichen antisense-transkripts gegen tnfr2
US8921330B2 (en)	2009-06-26	2014-12-30	Curna, Inc.	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
MX342945B (es)	2009-07-06	2016-10-18	Ontorii Inc *	Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
EP2454000A4 (de)	2009-07-17	2016-08-10	Ibis Biosciences Inc	Systeme zur identifizierung von biowirkstoffen
US8950604B2 (en) *	2009-07-17	2015-02-10	Ibis Biosciences, Inc.	Lift and mount apparatus
US9416409B2 (en)	2009-07-31	2016-08-16	Ibis Biosciences, Inc.	Capture primers and capture sequence linked solid supports for molecular diagnostic tests
ES2585360T3 (es)	2009-08-05	2016-10-05	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
WO2011017521A2 (en)	2009-08-06	2011-02-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
AP2015008874A0 (en)	2009-08-14	2015-11-30	Alnylam Pharmaceuticals Inc	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en)	2009-08-17	2012-06-21	Yale University	Methylation biomarkers and methods of use
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
EP2473522B1 (de)	2009-09-02	2016-08-17	Genentech, Inc.	Smoothened-mutant und verfahren zu seiner anwendung
WO2011041695A1 (en) *	2009-10-02	2011-04-07	Ibis Biosciences, Inc.	Determination of methylation status of polynucleotides
US9890408B2 (en) *	2009-10-15	2018-02-13	Ibis Biosciences, Inc.	Multiple displacement amplification
PH12012500734A1 (en)	2009-10-16	2012-11-26	Melinta Therapeutics Inc	Antimicrobial compounds and methods of making and using the same
JP2013508299A (ja)	2009-10-16	2013-03-07	リブ−エックスファーマシューティカルズ，インコーポレイテッド	抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
CN108456211A (zh) *	2009-10-16	2018-08-28	梅琳塔治疗公司	抗微生物化合物和其制备和使用方法
CA2778442A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
JP6147502B2 (ja)	2009-10-27	2017-06-14	スウィフトバイオサイエンシーズ，インコーポレイテッド	ポリヌクレオチドプライマー及びプローブ
KR20120136345A (ko)	2009-10-30	2012-12-18	노오쓰웨스턴 유니버시티	주형화된 나노컨쥬게이트
AU2010315867A1 (en)	2009-11-03	2012-06-21	University Of Virginia Patent Foundation	Versatile, visible method for detecting polymeric analytes
WO2011063403A1 (en)	2009-11-23	2011-05-26	Swift Biosciences, Inc.	Devices to extend single stranded target molecules
TWI537383B (zh)	2009-11-30	2016-06-11	建南德克公司	診斷及治療腫瘤之組合物及方法
CN102712927B (zh)	2009-12-16	2017-12-01	库尔纳公司	通过抑制膜结合转录因子肽酶，位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病
JP6031356B2 (ja)	2009-12-23	2016-11-24	カッパーアールエヌエー，インコーポレイテッド	Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
KR101891352B1 (ko)	2009-12-23	2018-08-24	큐알엔에이, 인크.	간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
KR101838305B1 (ko)	2009-12-29	2018-03-13	큐알엔에이, 인크.	ＮＲＦ1(ＮｕｃｌｅａｒＲｅｓｐｉｒａｔｏｒｙＦａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
CA2785177C (en)	2009-12-29	2019-09-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
JP5886757B2 (ja)	2010-01-04	2016-03-16	カッパーアールエヌエー，インコーポレイテッド	インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療
EP2521785B1 (de)	2010-01-06	2022-03-09	CuRNA, Inc.	Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
JP6027893B2 (ja)	2010-01-11	2016-11-16	カッパーアールエヌエー，インコーポレイテッド	性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2524042A2 (de)	2010-01-12	2012-11-21	Yale University	Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
EP2529015B1 (de)	2010-01-25	2017-11-15	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit rnase h1 mittels hemmung des natürlichen antisense-transkripts gegen rnase h1
CA2824843A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
KR101838308B1 (ko)	2010-02-22	2018-03-13	큐알엔에이, 인크.	피롤린-5-카르복실레이트 환원효소 1(ｐｙｃｒ1)에 대한 천연 안티센스 전사체의 억제에 의한 ｐｙｃｒ1과 관련된 질환의 치료
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
CA2787657A1 (en)	2010-02-23	2011-09-01	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
ES2743600T3 (es)	2010-03-12	2020-02-20	Brigham & Womens Hospital Inc	Métodos de tratamiento de los trastornos inflamatorios vasculares
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
WO2011115817A1 (en)	2010-03-16	2011-09-22	Isis Pharmaceuticals, Inc.	Methods of preparing 2'-o-substituted purine nucleosides
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US9095504B2 (en)	2010-03-24	2015-08-04	Rxi Pharmaceuticals Corporation	RNA interference in ocular indications
RU2615143C2 (ru)	2010-03-24	2017-04-04	Адвирна	Самодоставляющие PHKi соединения уменьшенного размера
IL265674B2 (en)	2010-03-24	2024-05-01	Phio Pharm Corp	Rana disorder in cutaneous and fibrotic symptoms
US8889350B2 (en)	2010-03-26	2014-11-18	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
AU2011230496B2 (en)	2010-03-26	2015-09-17	Integrated Dna Technologies, Inc.	Methods for enhancing nucleic acid hybridization
US9506057B2 (en)	2010-03-26	2016-11-29	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
US20130281510A1 (en)	2010-03-29	2013-10-24	Kumamoto University	siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
AU2011237630B2 (en)	2010-04-06	2016-01-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of CD274/PD-L1 gene
TWI644675B (zh)	2010-04-09	2018-12-21	可娜公司	藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
US20110269194A1 (en)	2010-04-20	2011-11-03	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
US20130260460A1 (en)	2010-04-22	2013-10-03	Isis Pharmaceuticals Inc	Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9127033B2 (en)	2010-04-28	2015-09-08	Isis Pharmaceuticals, Inc.	5′ modified nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (de)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modifizierte nukleoside und daraus hergestellte oligomere verbindungen
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
ES2625689T3 (es)	2010-04-29	2017-07-20	Ionis Pharmaceuticals, Inc.	Modulación de la expresión de transtiretina
CN102958941A (zh)	2010-05-03	2013-03-06	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
RU2693462C2 (ru)	2010-05-03	2019-07-03	Курна, Инк.	Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
EP2576783B1 (de)	2010-05-26	2017-11-29	CuRNA, Inc.	Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
WO2011150227A1 (en)	2010-05-26	2011-12-01	Qiagen Gaithersburg, Inc.	Quantitative helicase assay
AU2011261434B2 (en)	2010-06-02	2015-11-26	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2802049C (en)	2010-06-07	2018-07-10	Firefly Bioworks, Inc.	Scanning multifunctional particles
EP2580228B1 (de)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
WO2011156713A1 (en)	2010-06-11	2011-12-15	Vanderbilt University	Multiplexed interferometric detection system and method
EP2582397A4 (de)	2010-06-15	2014-10-29	Isis Pharmaceuticals Inc	Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
WO2011163466A1 (en)	2010-06-23	2011-12-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (nrg-1)
CA2805318A1 (en)	2010-07-14	2012-01-19	Curna, Inc.	Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
US20130225659A1 (en)	2010-07-19	2013-08-29	Isis Pharmaceuticals, Inc.	Modulation of nuclear-retained rna
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
CA2809457C (en)	2010-09-07	2019-07-30	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
DK2620428T3 (da)	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
EP2625197B1 (de)	2010-10-05	2016-06-29	Genentech, Inc.	Smoothened-mutant und verfahren zu seiner anwendung
ES2640755T3 (es)	2010-10-06	2017-11-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
US8648053B2 (en)	2010-10-20	2014-02-11	Rosalind Franklin University Of Medicine And Science	Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
US9222088B2 (en)	2010-10-22	2015-12-29	Curna, Inc.	Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
DK2633052T3 (en)	2010-10-27	2018-07-16	Curna Inc	TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
TW201307347A (zh)	2010-11-01	2013-02-16	Arqule Inc	經取代苯並－咪唑並－吡啶並－二氮呯化合物
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
AU2011325956B2 (en)	2010-11-12	2016-07-14	The General Hospital Corporation	Polycomb-associated non-coding RNAs
WO2012068405A2 (en)	2010-11-17	2012-05-24	Isis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
EP2643463B1 (de)	2010-11-23	2017-09-27	CuRNA, Inc.	Behandlung von nanog-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen nanog
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
EP2649182A4 (de)	2010-12-10	2015-05-06	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
US9127275B2 (en)	2010-12-10	2015-09-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
US9045749B2 (en)	2011-01-14	2015-06-02	The General Hospital Corporation	Methods targeting miR-128 for regulating cholesterol/lipid metabolism
JP6177692B2 (ja)	2011-02-02	2017-08-09	エクスカリアード・ファーマシューティカルズ，インク	結合組織増殖因子（ｃｔｇｆ）をターゲティングするアンチセンス化合物を用いた、ケロイドまたは肥厚性瘢痕の治療法
EP2670404B1 (de)	2011-02-02	2018-08-29	The Trustees of Princeton University	Sirtuin-modulatoren als modulatoren der virusproduktion
WO2012109157A2 (en)	2011-02-07	2012-08-16	The Governing Council Of The University Of Toronto	Bioprobes and methods of use thereof
EP3467109A1 (de)	2011-02-08	2019-04-10	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
EP2691121A4 (de)	2011-03-29	2015-08-26	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur hemmung der tmprss6-genexpression
US10086043B2 (en)	2011-04-03	2018-10-02	The General Hospital Corporation	Efficient protein expression in vivo using modified RNA (MOD-RNA)
WO2012149154A1 (en)	2011-04-26	2012-11-01	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
US9353371B2 (en)	2011-05-02	2016-05-31	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
JP6188686B2 (ja)	2011-06-09	2017-08-30	カッパーアールエヌエー，インコーポレイテッド	フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療
KR20260004562A (ko)	2011-06-21	2026-01-08	알닐람 파마슈티칼스 인코포레이티드	아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
WO2012177949A2 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibition of expression of protein c (proc) genes
CN103890000B (zh)	2011-06-21	2017-09-01	阿尔尼拉姆医药品有限公司	血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
EP2723390B1 (de)	2011-06-23	2017-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
US9222093B2 (en)	2011-06-30	2015-12-29	The University Of Hong Kong	Two-way, portable riboswitch mediated gene expression control device
US9605019B2 (en)	2011-07-19	2017-03-28	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
US20140328811A1 (en)	2011-08-01	2014-11-06	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
EP2742056B2 (de)	2011-08-11	2020-06-10	Ionis Pharmaceuticals, Inc.	Selektive antisense-verbindungen und ihre verwendungen
EP2751269B1 (de)	2011-08-29	2016-03-23	Ionis Pharmaceuticals, Inc.	Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
US10023861B2 (en)	2011-08-29	2018-07-17	Ionis Pharmaceuticals, Inc.	Oligomer-conjugate complexes and their use
ES2856091T3 (es)	2011-09-14	2021-09-27	Univ Northwestern	Nanoconjugados capaces de atravesar la barrera hematoencefálica
US9580708B2 (en)	2011-09-14	2017-02-28	Rana Therapeutics, Inc.	Multimeric oligonucleotides compounds
WO2013040548A2 (en)	2011-09-17	2013-03-21	Yale University	Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
US10184151B2 (en)	2011-10-11	2019-01-22	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
JP6532678B2 (ja)	2011-10-14	2019-06-19	ジェネンテック，インコーポレイテッド	抗ＨｔｒＡ１抗体及び使用方法
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
US9243291B1 (en)	2011-12-01	2016-01-26	Isis Pharmaceuticals, Inc.	Methods of predicting toxicity
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
US9970061B2 (en)	2011-12-27	2018-05-15	Ibis Biosciences, Inc.	Bioagent detection oligonucleotides
IL321422A (en)	2012-01-11	2025-08-01	Ionis Pharmaceuticals Inc	Compositions and methods for modulation of ikbkap splicing
EP2802666B1 (de)	2012-01-13	2018-09-19	Data2Bio	Genotypisierung durch eine sequenzierung der nächsten generation
EP2825672B1 (de)	2012-03-13	2019-02-13	Swift Biosciences, Inc.	Verfahren und zusammensetzungen für grössenkontrolliertes homopolymer-tailing von substratpolynucleotiden mittels einer nucleinsäurepolymerase
HUE040179T2 (hu)	2012-03-15	2019-02-28	Curna Inc	Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
WO2013138662A1 (en)	2012-03-16	2013-09-19	4S3 Bioscience, Inc.	Antisense conjugates for decreasing expression of dmpk
US10273474B2 (en)	2012-03-30	2019-04-30	Washington University	Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
JP2015518485A (ja)	2012-04-20	2015-07-02	アプタミアールセラピューティクスインコーポレイテッド	熱発生のｍｉＲＮＡ調節剤
WO2013159108A2 (en)	2012-04-20	2013-10-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
EP3597741A1 (de)	2012-04-27	2020-01-22	Duke University	Genetische korrektur mutierter gene
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
SG11201407483YA (en)	2012-05-16	2014-12-30	Rana Therapeutics Inc	Compositions and methods for modulating smn gene family expression
EP3511416A1 (de)	2012-05-16	2019-07-17	Translate Bio MA, Inc.	Zusammensetzungen und verfahren zur modulation von genexpression
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
WO2013173789A2 (en)	2012-05-17	2013-11-21	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
US9487780B2 (en)	2012-06-01	2016-11-08	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
US9828602B2 (en)	2012-06-01	2017-11-28	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
WO2013185097A1 (en)	2012-06-08	2013-12-12	The Regents Of The University Of Michigan	Ultrasound-triggerable agents for tissue engineering
KR20240148947A (ko)	2012-07-13	2024-10-11	웨이브 라이프 사이언시스 리미티드	키랄 제어
SG11201500239VA (en)	2012-07-13	2015-03-30	Wave Life Sciences Japan	Asymmetric auxiliary group
SG11201500243WA (en)	2012-07-13	2015-04-29	Shin Nippon Biomedical Lab Ltd	Chiral nucleic acid adjuvant
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
WO2014022852A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US9403865B2 (en)	2012-08-15	2016-08-02	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
DK2892617T3 (en)	2012-09-06	2018-09-03	Univ Chicago	ANTISENSE POLYNUCLEOTIDES FOR INDUCTION OF EXON SKIPPING AND PROCEDURES FOR TREATING DYSTROPHIES
EP2906699A4 (de)	2012-10-11	2016-06-08	Ionis Pharmaceuticals Inc	Oligomere verbindungen mit bicyclischen nukleosiden und verwendungen davon
CA2887884A1 (en)	2012-10-12	2014-04-17	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
EP4144845B1 (de)	2012-10-12	2024-04-24	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen und verwendungen davon
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA3201145A1 (en)	2012-10-26	2014-05-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
HK1214831A1 (zh)	2012-11-05	2016-08-05	Foundation Medicine, Inc.	新型融合分子及其应用
US9695475B2 (en)	2012-12-11	2017-07-04	Ionis Pharmaceuticals, Inc.	Competitive modulation of microRNAs
US10980804B2 (en)	2013-01-18	2021-04-20	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
WO2014121287A2 (en)	2013-02-04	2014-08-07	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
RU2745324C2 (ru)	2013-03-14	2021-03-23	Ионис Фармасьютикалз, Инк.	Композиции и способы модулирования экспрессии tau
BR112015022308A8 (pt)	2013-03-14	2018-01-23	Andes Biotechnologies S A	oligonucleotídeos antissenso para o tratamento de células-tronco cancerosas
CN114015692B (zh)	2013-03-14	2024-12-31	阿尔尼拉姆医药品有限公司	补体组分C5 iRNA组合物及其使用方法
CA2905557A1 (en)	2013-03-14	2014-09-25	Andes Biotechnologies S.A.	Methods for detecting and treating multiple myeloma
US9347095B2 (en)	2013-03-15	2016-05-24	Bio-Rad Laboratories, Inc.	Digital assays for mutation detection
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
CA2918194C (en)	2013-03-27	2022-12-06	The General Hospital Corporation	Methods and agents for treating alzheimer's disease
JP2016522679A (ja)	2013-04-04	2016-08-04	プレジデントアンドフェローズオブハーバードカレッジ	ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
US9677075B2 (en)	2013-04-23	2017-06-13	Northwestern University	Metal-ligand coordination polymer nanoparticles and methods for making
PE20152002A1 (es) *	2013-05-01	2016-01-21	Isis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de ttr y vhb
TWI727917B (zh)	2013-05-22	2021-05-21	美商阿尼拉製藥公司	ＴＭＰＲＳＳ６ｉＲＮＡ組成物及其使用方法
EP3412774A1 (de)	2013-05-22	2018-12-12	Alnylam Pharmaceuticals, Inc.	Serpina1-irna-zusammensetzungen und verfahren zur verwendung davon
EP3004396B1 (de)	2013-06-06	2019-10-16	The General Hospital Corporation	Zusammensetzungen zur krebsbehandlung
DK3007704T3 (da)	2013-06-13	2021-03-29	Antisense Therapeutics Ltd	Kombinationsterapi til akromegali
WO2014205451A2 (en)	2013-06-21	2014-12-24	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of target nucleic acids
JP6617702B2 (ja)	2013-07-15	2019-12-11	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｆｔｙ７２０のアザサイクリック拘束アナログ
TWI772856B (zh)	2013-07-19	2022-08-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
EP3027617B1 (de)	2013-07-31	2026-02-18	Ionis Pharmaceuticals, Inc.	Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
GB201313897D0 (en) *	2013-08-02	2013-09-18	Maersk Olie & Gas	Conformance control in enhanced oil recovery
WO2015021432A1 (en)	2013-08-08	2015-02-12	The Scripps Research Institute	A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
EP3038623A4 (de)	2013-09-09	2017-04-19	Melinta Therapeutics, Inc.	Antimikrobielle verbindungen und verfahren zur herstellung und verwendung davon
MX2016002975A (es)	2013-09-09	2016-10-21	Melinta Therapeutics Inc	Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos.
WO2015042447A1 (en)	2013-09-20	2015-03-26	Isis Pharmaceuticals, Inc.	Targeted therapeutic nucleosides and their use
TWI669393B (zh)	2013-10-02	2019-08-21	艾爾妮蘭製藥公司	抑制ｌｅｃｔ２基因表現之組合物及方法
BR122020001264B1 (pt)	2013-10-04	2022-11-22	Icahn School Of Medicine At Mount Sinai	Ácido ribonucleico de fita dupla (dsrna) para inibição da expressão de alas1, composição farmacêutica para inibição da expressão de um gene alas1, métodos de inibição da expressão de alas1 em uma célula e para diminuir um nível de uma porfirina ou de um precursor de porfirina em uma célula, usos de um dsrna, método para avaliar o nível de mrna de alas1 extracelular em circulação em um indivíduo, composição e uso da mesma
EP3055426B1 (de)	2013-10-09	2019-06-19	The United States of America as represented by The Secretary Department of Health and Human Services	Nachweis von hepatitis delta virus (hdv) zur diagnose und behandlung von sjögren-syndrom und lymphom
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
CA2928779A1 (en)	2013-10-21	2015-04-30	The General Hospital Corporation	Methods relating to circulating tumor cell clusters and the treatment of cancer
US10301622B2 (en)	2013-11-04	2019-05-28	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
WO2015070173A1 (en)	2013-11-08	2015-05-14	Isis Pharmaceuticals, Inc.	Compounds and methods for detecting oligonucleotides
CN106061488B (zh)	2013-12-02	2021-04-09	菲奥医药公司	癌症的免疫治疗
US20170268000A1 (en)	2013-12-02	2017-09-21	Ionis Pharmaceuticals, Inc.	Antisense compounds and uses thereof
JP6527516B2 (ja)	2013-12-03	2019-06-05	ノースウェスタンユニバーシティ	リポソーム粒子、前述のものを作製する方法及びその使用
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
IL314045A (en)	2013-12-12	2024-09-01	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
EP3082840B1 (de)	2013-12-20	2021-03-24	The General Hospital Corporation	Verfahren und tests im zusammenhang mit zirkulierenden tumorzellen
EP3095460A4 (de)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
ES2917473T3 (es)	2014-01-16	2022-07-08	Wave Life Sciences Ltd	Diseño quiral
CA2937539A1 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
KR102592370B1 (ko)	2014-02-11	2023-10-25	알닐람 파마슈티칼스 인코포레이티드	케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
WO2015142910A1 (en)	2014-03-17	2015-09-24	Isis Pharmaceuticals, Inc.	Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
US10006027B2 (en)	2014-03-19	2018-06-26	Ionis Pharmaceuticals, Inc.	Methods for modulating Ataxin 2 expression
EP3119888B1 (de)	2014-03-19	2021-07-28	Ionis Pharmaceuticals, Inc.	Zusammensetzungen zur modulierung der ataxin-2-expression
SI3757214T1 (sl)	2014-04-01	2022-08-31	Biogen Ma Inc.	Sestave za moduliranje izražanja SOD-1
EP3129493B1 (de)	2014-04-09	2021-07-07	The Scripps Research Institute	Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
EP3647318B1 (de)	2014-04-28	2021-06-30	Ionis Pharmaceuticals, Inc.	Verbindungsmodifizierte oligomerverbindungen
CA2947270A1 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic acids targeting mdm2 or mycn
RS59182B1 (sr)	2014-05-01	2019-10-31	Ionis Pharmaceuticals Inc	Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
ES2812099T3 (es)	2014-05-01	2021-03-16	Ionis Pharmaceuticals Inc	Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
ES2844593T3 (es)	2014-05-01	2021-07-22	Ionis Pharmaceuticals Inc	Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
WO2015179693A1 (en)	2014-05-22	2015-11-26	Isis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
MX382901B (es)	2014-05-22	2025-03-13	Alnylam Pharmaceuticals Inc	Composiciones de angiotensinogeno (agt) arni y métodos de uso de las mismas.
WO2015187541A1 (en)	2014-06-02	2015-12-10	Children's Medical Center Corporation	Methods and compositions for immunomodulation
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN106661580B (zh)	2014-06-10	2022-02-15	鹿特丹伊拉斯谟大学医疗中心	用于治疗庞帕病的反义寡核苷酸
WO2015200377A1 (en)	2014-06-24	2015-12-30	Abbott Molecular Inc.	Detection of single nucleotide polymorphisms in human kras
EP3760208B1 (de)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
AU2015298263B2 (en)	2014-07-31	2020-05-14	Anji Pharmaceuticals, Inc.	ApoE mimetic peptides and higher potency to clear plasma cholesterol
AU2015305482B2 (en)	2014-08-19	2021-04-01	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
EP3183345B1 (de)	2014-08-20	2021-06-16	Northwestern University	Biokompatible polymernanopartikel-nukleinsäurekonjugate mit unendlicher koordination zur antisense-genregulation
EP3185910A4 (de)	2014-08-29	2018-01-10	Children's Medical Center Corporation	Verfahren und zusammensetzungen zur krebsbehandlung
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
LT3185957T (lt)	2014-08-29	2022-09-26	Alnylam Pharmaceuticals, Inc.	Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
KR102506169B1 (ko)	2014-09-05	2023-03-08	피오 파마슈티칼스 코프.	Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
US10436802B2 (en)	2014-09-12	2019-10-08	Biogen Ma Inc.	Methods for treating spinal muscular atrophy
WO2016049512A1 (en)	2014-09-26	2016-03-31	University Of Massachusetts	Rna-modulating agents
TWI755351B (zh)	2014-10-10	2022-02-21	美商艾爾妮蘭製藥公司	用於抑制ｈａｏ１（羥酸氧化酶１（乙醇酸鹽氧化酶））基因表現的組合物及方法
EP3207138B1 (de)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
WO2016069694A2 (en)	2014-10-30	2016-05-06	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
US10287584B2 (en)	2014-11-12	2019-05-14	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of COMP
CA2964979A1 (en)	2014-11-14	2016-05-19	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of proteins
CN107250362B (zh)	2014-11-17	2021-10-22	阿尔尼拉姆医药品有限公司	载脂蛋白C3(APOC3)iRNA组合物及其使用方法
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
AU2015360794B2 (en)	2014-12-08	2021-07-08	The Board Of Regents Of The University Of Texas System	Lipocationic polymers and uses thereof
EP4372091A3 (de)	2014-12-12	2024-07-31	Tod M. Woolf	Zusammensetzungen und verfahren zur bearbeitung von nukleinsäuren in zellen unter verwendung von oligonukleotiden
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
WO2016115490A1 (en)	2015-01-16	2016-07-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of dux4
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
JP6929791B2 (ja)	2015-02-09	2021-09-01	デュークユニバーシティ	エピゲノム編集のための組成物および方法
JP2018510621A (ja)	2015-02-13	2018-04-19	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
US12129471B2 (en)	2015-02-23	2024-10-29	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
BR112017019349A2 (pt)	2015-03-11	2018-06-05	Melinta Therapeutics Inc	compostos antimicrobianos e métodos de fabricação e uso dos mesmos
CN115537396A (zh)	2015-03-27	2022-12-30	哈佛学院校长同事会	经过修饰的t细胞及其制备和使用方法
WO2016164463A1 (en)	2015-04-07	2016-10-13	The General Hospital Corporation	Methods for reactivating genes on the inactive x chromosome
SI3283500T1 (sl)	2015-04-08	2020-12-31	The University Of Chicago	Sestavki in postopki za popravilo medenično ramenske distrofije tipa 2C z uporabo preskakovanja eksonov
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
WO2016210241A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
IL318703A (en)	2015-06-29	2025-03-01	Caris Science Inc	Therapeutic oligonucleotides
US11414657B2 (en)	2015-06-29	2022-08-16	Ionis Pharmaceuticals, Inc.	Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
KR20180026739A (ko)	2015-07-06	2018-03-13	알엑스아이 파마슈티칼스 코포레이션	슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
MY192997A (en)	2015-07-10	2022-09-20	Ionis Pharmaceuticals Inc	Modulators of diacyglycerol acyltransferase 2 (dgat2)
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
CN108025089A (zh)	2015-07-22	2018-05-11	波涛生命科学有限公司	寡核苷酸组合物及其方法
US10941176B2 (en)	2015-07-28	2021-03-09	Caris Science, Inc.	Therapeutic oligonucleotides
WO2017021961A1 (en)	2015-08-04	2017-02-09	Yeda Research And Development Co. Ltd.	Methods of screening for riboswitches and attenuators
SG10202007937SA (en)	2015-09-02	2020-09-29	Alnylam Pharmaceuticals Inc	PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11247968B2 (en)	2015-09-14	2022-02-15	The Board Of Regents Of The University Of Texas System	Lipocationic dendrimers and uses thereof
US20190048340A1 (en)	2015-09-24	2019-02-14	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
CN108366990B (zh)	2015-09-24	2021-09-03	加利福尼亚大学董事会	合成的鞘脂类分子、药物、它们的合成方法及治疗方法
SG10201913209WA (en)	2015-09-24	2020-02-27	Ionis Pharmaceuticals Inc	Modulators of kras expression
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
US10709812B2 (en)	2015-09-29	2020-07-14	The Regents Of The University Of Michigan	Biodegradable hydrogel for tissue expansion
US11970710B2 (en)	2015-10-13	2024-04-30	Duke University	Genome engineering with Type I CRISPR systems in eukaryotic cells
US11021707B2 (en)	2015-10-19	2021-06-01	Phio Pharmaceuticals Corp.	Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
EP4279084B1 (de)	2015-10-28	2025-06-11	Vertex Pharmaceuticals Inc.	Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
NZ741780A (en)	2015-10-30	2019-11-29	Genentech Inc	Anti-htra1 antibodies and methods of use thereof
WO2017075670A1 (en)	2015-11-05	2017-05-11	Children's Hospital Los Angeles	"mobilizing leukemia cells"
KR20250078597A (ko)	2015-11-06	2025-06-02	아이오니스 파마수티컬즈, 인코포레이티드	아포리포프로테인 (a) 발현 조정
WO2017077386A1 (en)	2015-11-06	2017-05-11	Crispr Therapeutics Ag	Materials and methods for treatment of glycogen storage disease type 1a
HRP20241087T1 (hr)	2015-11-06	2024-11-08	Ionis Pharmaceuticals, Inc.	Konjugirani protusmisleni spojevi za upotrebu u terapiji
WO2017087708A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
KR102787119B1 (ko)	2015-11-30	2025-03-27	듀크 유니버시티	유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
JP6932698B2 (ja)	2015-12-01	2021-09-08	クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲＴｈｅｒａｐｅｕｔｉｃｓＡＧ	アルファ１アンチトリプシン欠乏症の治療のための材料および方法
WO2017096395A1 (en)	2015-12-04	2017-06-08	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
KR20210157474A (ko)	2015-12-07	2021-12-28	젠자임 코포레이션	Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
EP3387127A1 (de)	2015-12-07	2018-10-17	Erasmus University Medical Center Rotterdam	Enzymatische ersatztherapie und antisense-therapie für pompe-krankheit
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
EP3394260B1 (de)	2015-12-23	2021-02-17	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyothrophischer lateraler sklerose und/oder frontotemporaler demenz
WO2017117496A1 (en)	2015-12-31	2017-07-06	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
AU2017205462A1 (en)	2016-01-05	2018-06-07	Ionis Pharmaceuticals, Inc.	Methods for reducing LRRK2 expression
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
EP3411078A1 (de)	2016-02-02	2018-12-12	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
EP3411396A1 (de)	2016-02-04	2018-12-12	Curis, Inc.	Smoothened-mutant und verfahren zur verwendung davon
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017147087A1 (en)	2016-02-25	2017-08-31	The Brigham And Women's Hospital, Inc.	Treatment methods for fibrosis targeting smoc2
EP3423581A4 (de)	2016-03-04	2020-03-04	Rhode Island Hospital	Targeting von mikrorna zur krebsbehandlung
CA3013797A1 (en)	2016-03-09	2017-09-14	Ionis Pharmaceuticals, Inc.	Methods and compositions for inhibiting pmp22 expression
US11083799B2 (en)	2016-03-16	2021-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
US10961271B2 (en)	2016-03-16	2021-03-30	Ionis Pharmaceuticals, Inc.	Methods of modulating KEAP1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
US10731166B2 (en)	2016-03-18	2020-08-04	Caris Science, Inc.	Oligonucleotide probes and uses thereof
US20190127713A1 (en)	2016-04-13	2019-05-02	Duke University	Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
US20190142856A1 (en)	2016-04-13	2019-05-16	Ionis Pharmaceuticals, Inc.	Methods for reducing c9orf72 expression
AU2017252023B2 (en)	2016-04-18	2024-05-02	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
IL299516A (en)	2016-05-06	2023-02-01	Astrazeneca Ab	Oligonucleotides conjugated to the GLP-1 receptor ligand complex and their uses
US11098047B2 (en)	2016-05-06	2021-08-24	BioVersys AG	Antimicrobials and methods of making and using same
EP3458032A4 (de)	2016-05-16	2019-12-25	The Board of Regents of The University of Texas System	Kationische sulfonamid-aminolipide und amphiphile zwitterionische aminolipide
IL298701B2 (en)	2016-05-25	2024-03-01	Caris Science Inc	Oligonucleotide probes and uses thereof
EP3469083A1 (de)	2016-06-10	2019-04-17	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
EP3472350B1 (de)	2016-06-15	2022-08-17	Streck, Inc.	Test und verfahren zu bestimmung mikrobieller resistenz
CA3023514A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
ES2929047T3 (es)	2016-06-24	2022-11-24	Scripps Research Inst	Transportador de nucleósido trifosfato novedoso y usos del mismo
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
CA3029119A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
US11174469B2 (en)	2016-06-29	2021-11-16	Crispr Therapeutics Ag	Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
CN109843914B (zh)	2016-07-06	2024-03-15	沃泰克斯药物股份有限公司	用于治疗疼痛相关病症的材料和方法
US11801313B2 (en)	2016-07-06	2023-10-31	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
US11253601B2 (en)	2016-07-11	2022-02-22	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
IL264216B2 (en)	2016-07-15	2024-04-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulation of smn2
EP4275747A3 (de)	2016-07-19	2024-01-24	Duke University	Therapeutische anwendungen von cpf1-basierter genomeditierung
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
EP3500581A4 (de)	2016-08-17	2021-10-06	Solstice Biologics, Ltd.	Polynukleotidkonstrukte
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
SG10201607303YA (en)	2016-09-01	2018-04-27	Agency Science Tech & Res	Antisense oligonucleotides to induce exon skipping
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
JOP20190065A1 (ar)	2016-09-29	2019-03-28	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن tau
KR20190065341A (ko)	2016-10-06	2019-06-11	아이오니스 파마수티컬즈, 인코포레이티드	올리고머 화합물들의 접합 방법
SG10201609048RA (en)	2016-10-28	2018-05-30	Agency Science Tech & Res	Antisense oligonucleotides
WO2018081817A2 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
WO2018089582A1 (en)	2016-11-10	2018-05-17	San Diego State University Research Foundation	Compounds for fluorescence sensing of duplex formation
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
WO2018102745A1 (en)	2016-12-02	2018-06-07	Cold Spring Harbor Laboratory	Modulation of lnc05 expression
AU2017378153B2 (en)	2016-12-13	2024-03-28	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
SG10201913552UA (en)	2016-12-16	2020-03-30	Alnylam Pharmaceuticals Inc	Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
WO2018136758A1 (en)	2017-01-23	2018-07-26	Regeneron Pharmaceuticals, Inc.	Hsd17b13 variants and uses thereof
WO2018154462A2 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US11920148B2 (en)	2017-02-22	2024-03-05	Crispr Therapeutics Ag	Compositions and methods for gene editing
US11407997B2 (en)	2017-02-22	2022-08-09	Crispr Therapeutics Ag	Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
US20200040061A1 (en)	2017-02-22	2020-02-06	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018154439A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
JOP20190215A1 (ar)	2017-03-24	2019-09-19	Ionis Pharmaceuticals Inc	مُعدّلات التعبير الوراثي عن pcsk9
US20180284123A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
US11484570B2 (en)	2017-04-14	2022-11-01	University Of Massachusetts	Targeting cell tropism receptors to inhibit cytomegalovirus infection
CA3058966A1 (en)	2017-04-14	2018-10-18	Tollnine, Inc.	Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
CN118384268A (zh)	2017-04-18	2024-07-26	阿尔尼拉姆医药品有限公司	具有乙肝病毒（hbv）感染的受试者的治疗方法
EP3612152A4 (de)	2017-04-19	2021-02-17	Phio Pharmaceuticals Corp.	Topische verabreichung von nukleinsäureverbindungen
JP7801082B2 (ja)	2017-04-20	2026-01-16	シンセナアーゲー	トリシクロｄｎａヌクレオシドを含む改変オリゴマー化合物およびその使用
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018195486A1 (en)	2017-04-21	2018-10-25	The Broad Institute, Inc.	Targeted delivery to beta cells
US11433131B2 (en)	2017-05-11	2022-09-06	Northwestern University	Adoptive cell therapy using spherical nucleic acids (SNAs)
IL270415B2 (en)	2017-05-12	2024-08-01	Crispr Therapeutics Ag	Materials and methods for cell engineering and their uses in immuno-oncology
EP3645546A4 (de)	2017-06-30	2021-12-01	Solstice Biologics, Ltd.	Chirale phosphoramidithilfsmittel und verfahren zu ihrer verwendung
US20200163987A1 (en)	2017-07-10	2020-05-28	Genzyme Corporation	Methods and compositions for treating a bleeding event in a subject having hemophilia
MA49716A (fr)	2017-07-11	2021-04-07	Scripps Research Inst	Incorporation de nucléotides non naturels et procédés d'utilisationin vivo
TW202426655A (zh)	2017-07-11	2024-07-01	美商新索思股份有限公司	非天然核苷酸之導入及其方法
JP7277432B2 (ja)	2017-07-13	2023-05-19	アルナイラムファーマシューティカルズ，インコーポレイテッド	乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法
KR20200028997A (ko)	2017-07-13	2020-03-17	노오쓰웨스턴 유니버시티	올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
MA49767A (fr)	2017-08-03	2021-05-26	Synthorx Inc	Conjugués de cytokine pour le traitement de maladies auto-immunes
EP3668984A4 (de)	2017-08-18	2021-09-08	Ionis Pharmaceuticals, Inc.	Modulation des notch-signalweges zur behandlung von atemwegserkrankungen
WO2019051173A1 (en)	2017-09-08	2019-03-14	Ionis Pharmaceuticals, Inc.	MODULATORS OF SMAD7 EXPRESSION
US11999953B2 (en)	2017-09-13	2024-06-04	The Children's Medical Center Corporation	Compositions and methods for treating transposon associated diseases
BR112020005230A2 (pt)	2017-09-19	2020-09-24	Alnylam Pharmaceuticals, Inc.	composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
CN111684070A (zh)	2017-10-17	2020-09-18	克里斯珀医疗股份公司	用于a型血友病基因编辑的组合物和方法
WO2019081982A1 (en)	2017-10-26	2019-05-02	Crispr Therapeutics Ag	SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
SG11202002940QA (en)	2017-11-01	2020-04-29	Alnylam Pharmaceuticals Inc	Complement component c3 irna compositions and methods of use thereof
US20210363521A1 (en)	2017-11-09	2021-11-25	Vertex Pharmaceuticals Incorporated	CRISPR/CAS Systems For Treatment of DMD
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
EP3714055A1 (de)	2017-11-21	2020-09-30	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von autosomal-dominanter retinitis pigmentosa
SG11202005147WA (en)	2017-12-05	2020-06-29	Vertex Pharma	Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
US11578323B2 (en)	2017-12-14	2023-02-14	Bayer Healthcare Llc	RNA-programmable endonuclease systems and their use in genome editing and other applications
WO2019118916A1 (en)	2017-12-14	2019-06-20	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
BR112020012088A2 (pt)	2017-12-18	2020-11-17	Alnylam Pharmaceuticals, Inc.	composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
WO2019123430A1 (en)	2017-12-21	2019-06-27	Casebia Therapeutics Llp	Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
AU2018393050A1 (en)	2017-12-21	2020-06-18	Bayer Healthcare Llc	Materials and methods for treatment of Usher Syndrome Type 2A
KR102776907B1 (ko)	2017-12-29	2025-03-11	더 스크립스 리서치 인스티튜트	비천연 염기쌍 조성물 및 사용 방법
US12178855B2 (en)	2018-01-10	2024-12-31	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
EA202091693A1 (ru)	2018-01-12	2021-04-14	Бристол-Маерс Сквибб Компани	Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
EP3737762A1 (de)	2018-01-12	2020-11-18	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur geneditierung von genen durch transferrin-targeting
MX2020007433A (es)	2018-01-12	2020-09-14	Bristol Myers Squibb Co	Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
MX2020007369A (es)	2018-01-15	2020-10-28	Ionis Pharmaceuticals Inc	Moduladores de la expresion de dnm2.
US12509492B2 (en)	2018-01-19	2025-12-30	Duke University	Genome engineering with CRISPR-Cas systems in eukaryotes
JP7652567B2 (ja)	2018-01-19	2025-03-27	シンセナアーゲー	トリシクロ－ｄｎａヌクレオシド前駆体およびそれを調製するためのプロセス
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
MA51787A (fr)	2018-02-05	2020-12-16	Vertex Pharma	Substances et méthodes de traitement d'hémoglobinopathies
WO2019150203A1 (en)	2018-02-05	2019-08-08	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
AU2019218987B2 (en)	2018-02-12	2025-04-24	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
WO2019161310A1 (en)	2018-02-16	2019-08-22	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting fibrinogen-alpha
CN112004547A (zh)	2018-02-26	2020-11-27	新索思股份有限公司	Il-15缀合物及其用途
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
EP3759127A4 (de)	2018-03-02	2022-03-30	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation des amyloid-beta-vorläuferproteins
CA3092497A1 (en)	2018-03-19	2019-09-26	Crispr Therapeutics Ag	Novel rna-programmable endonuclease systems and uses thereof
US11661601B2 (en)	2018-03-22	2023-05-30	Ionis Pharmaceuticals, Inc.	Methods for modulating FMR1 expression
JP7474702B2 (ja)	2018-03-28	2024-04-25	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
CA3095545A1 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
US20210155959A1 (en)	2018-04-06	2021-05-27	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
PE20201349A1 (es)	2018-04-11	2020-11-30	Ionis Pharmaceuticals Inc	Moduladores de la expresion de ezh2
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CN112041436A (zh)	2018-04-27	2020-12-04	西雅图儿童医院（Dba西雅图儿童研究所）	雷帕霉素抗性细胞
EP3788065B1 (de)	2018-04-30	2025-08-27	The Children's Hospital Of Philadelphia	Verbesserung von anämien durch kombination von wirkstoffen
WO2019213571A1 (en)	2018-05-03	2019-11-07	The Trustees Of Wheaton College	Improved membranes for nanopore sensing applications
SG11202010012PA (en)	2018-05-09	2020-11-27	Ionis Pharmaceuticals Inc	Compounds and methods for reducing fxi expression
WO2019217708A1 (en)	2018-05-09	2019-11-14	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing atxn3 expression
EP3790893A4 (de)	2018-05-11	2022-03-16	University Of Massachusetts	Verfahren zur verbesserung der leptinempfindlichkeit zur behandlung von fettleibigkeit und diabetes
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
AU2019287635B2 (en)	2018-06-14	2026-02-12	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing STMN2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
WO2020018558A1 (en)	2018-07-17	2020-01-23	Aronora, Inc.	Methods for safely reducing thrombopoietin
CA3106986A1 (en)	2018-07-25	2020-01-30	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing atxn2 expression
MX2021001056A (es)	2018-08-13	2021-04-12	Alnylam Pharmaceuticals Inc	Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
EP3837367A1 (de)	2018-08-16	2021-06-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
EA202190581A1 (ru)	2018-08-20	2021-07-13	Рогкон, Инк.	Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
US12281308B2 (en)	2018-08-29	2025-04-22	University Of Massachusetts	Inhibition of protein kinases to treat Friedreich ataxia
EP3620520A1 (de)	2018-09-10	2020-03-11	Universidad del Pais Vasco	Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
AU2019339509A1 (en)	2018-09-14	2021-05-13	Northwestern University	Programming protein polymerization with DNA
US20210332367A1 (en)	2018-09-18	2021-10-28	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TWI869213B (zh)	2018-09-19	2025-01-01	美商Ionis製藥公司	Pnpla3表現之調節劑
EP3856931B1 (de)	2018-09-25	2023-10-11	Co-Diagnostics, Inc.	Allelspezifische konstruktion von kooperativen primern für verbesserte genotypisierung von nukleinsäurevarianten
JP7520826B2 (ja)	2018-10-17	2024-07-23	クリスパー・セラピューティクス・アクチェンゲゼルシャフト	導入遺伝子を送達するための組成物および方法
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
CN113260374A (zh)	2018-11-08	2021-08-13	新索思股份有限公司	白介素10缀合物及其用途
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
AU2019380940A1 (en)	2018-11-15	2021-06-03	Ionis Pharmaceuticals, Inc.	Modulators of IRF5 expression
EP3884053A4 (de)	2018-11-21	2023-02-01	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur verringerung der prionenexpression
CA3121191A1 (en)	2018-11-28	2020-06-04	Crispr Therapeutics Ag	Optimized mrna encoding cas9 for use in lnps
EP3894559A4 (de)	2018-12-03	2023-04-05	Triplet Therapeutics, Inc.	Verfahren zur behandlung von störungen der trinukleotid-repeat-expansion im zusammenhang mit mlh3-aktivität
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
DK4285929T3 (da)	2018-12-20	2025-12-22	Humabs Biomed Sa	Kombinationsterapi mod hbv
EP3898977A1 (de)	2018-12-20	2021-10-27	Praxis Precision Medicines, Inc.	Zusammensetzungen und verfahren zur behandlung von kcnt1-assoziierten erkrankungen
CA3124415A1 (en)	2018-12-21	2020-06-25	Northwestern University	Use of annexins in preventing and treating muscle membrane injury
SG11202106378VA (en)	2018-12-21	2021-07-29	Ionis Pharmaceuticals Inc	Modulators of hsd17b13 expression
US20220062299A1 (en)	2018-12-26	2022-03-03	Northwestern University	Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
CA3126933A1 (en)	2019-01-16	2020-07-23	Genzyme Corporation	Serpinc1 irna compositions and methods of use thereof
TW202214854A (zh)	2019-01-31	2022-04-16	美商Ionis製藥公司	Yap1表現之調節劑
CA3127689A1 (en)	2019-02-06	2020-08-13	Synthorx, Inc.	Il-2 conjugates and methods of use thereof
WO2020168362A1 (en)	2019-02-15	2020-08-20	Crispr Therapeutics Ag	Gene editing for hemophilia a with improved factor viii expression
MX2021010152A (es)	2019-02-27	2021-09-14	Ionis Pharmaceuticals Inc	Moduladores de la expresion de malat1.
WO2020181144A1 (en)	2019-03-06	2020-09-10	Northwestern University	Hairpin-like oligonucleotide-conjugated spherical nucleic acid
CA3139919A1 (en)	2019-03-11	2020-09-17	Ochsner Health System	Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
SG11202109741VA (en)	2019-03-12	2021-10-28	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
MD3947684T2 (ro)	2019-03-29	2025-10-31	Ionis Pharmaceuticals Inc	Compuși și metode pentru modularea UBE3A-ATS
KR20220036914A (ko)	2019-05-13	2022-03-23	비르 바이오테크놀로지, 인코포레이티드	B형 간염 바이러스(hbv) 감염을 치료하기 위한 조성물 및 방법
US20220243203A1 (en)	2019-05-28	2022-08-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing fus expression
CA3140112A1 (en)	2019-05-31	2020-12-03	Streck, Inc.	Detection of antibiotic resistance genes
IL288941B2 (en)	2019-06-14	2025-10-01	Scripps Research Inst	Reagents and methods for replication, transcription, and translation in semisynthetic organisms
EP4660307A2 (de)	2019-07-26	2025-12-10	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur gfap-modulation
WO2021022109A1 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030778A1 (en)	2019-08-15	2021-02-18	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds and uses thereof
WO2021030706A1 (en)	2019-08-15	2021-02-18	Synthorx, Inc.	Immuno oncology combination therapies with il-2 conjugates
US12344648B2 (en)	2019-08-23	2025-07-01	Synthrox, Inc.	IL-15 conjugates and uses thereof
MX2022002689A (es)	2019-09-03	2022-04-07	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
AU2020347154A1 (en)	2019-09-10	2022-03-03	Synthorx, Inc.	IL-2 conjugates and methods of use to treat autoimmune diseases
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
EP4038189A1 (de)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
JP7757277B2 (ja)	2019-10-14	2025-10-21	アストラゼネカ・アクチエボラーグ	Ｐｎｐｌａ３発現のモジュレーター
US12486512B2 (en)	2019-10-18	2025-12-02	Alnylam Pharmaceuticals, Inc.	Solute carrier family member iRNA compositions and methods of use thereof
AU2020369515A1 (en)	2019-10-22	2022-04-21	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
US20240168004A1 (en)	2019-10-31	2024-05-23	The Trustees Of Wheaton College	Design and characterization of multilayered structures for support of lipid bilayers
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
CN119499394A (zh)	2019-11-01	2025-02-25	阿尔尼拉姆医药品有限公司	亨廷顿（HTT）iRNA药剂组合物及其使用方法
EP4054644A1 (de)	2019-11-04	2022-09-14	Synthorx, Inc.	Interleukin-10-konjugate und deren verwendungen
TWI877247B (zh)	2019-11-13	2025-03-21	美商阿尼拉製藥公司	用於治療血管收縮素原相關病症之方法及組成物
WO2021102373A1 (en)	2019-11-22	2021-05-27	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
JP7684298B2 (ja)	2019-11-27	2025-05-27	クリスパー・セラピューティクス・アクチェンゲゼルシャフト	Ｒｎａ分子を合成する方法
PH12022551394A1 (en)	2019-12-13	2023-09-11	Alnylam Pharmaceuticals Inc	Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
EP4077674A1 (de)	2019-12-18	2022-10-26	Alia Therapeutics S.R.L.	Zusammensetzungen und verfahren zur behandlung von retinitis pigmentosa
WO2021142245A1 (en)	2020-01-10	2021-07-15	Translate Bio, Inc.	Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
WO2021154705A1 (en)	2020-01-27	2021-08-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
AU2021220765A1 (en)	2020-02-10	2022-09-01	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing VEGF-A expression
JP7735288B2 (ja)	2020-02-18	2025-09-08	アルナイラムファーマシューティカルズ，インコーポレイテッド	アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
IL295759A (en)	2020-02-28	2022-10-01	Tallac Therapeutics Inc	Transglutaminase mediated coupling
CN120505310A (zh)	2020-02-28	2025-08-19	Ionis制药公司	用于调节smn2的化合物和方法
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
WO2021178736A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021188611A1 (en)	2020-03-18	2021-09-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
US20230190785A1 (en)	2020-03-30	2023-06-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
EP4127134A4 (de)	2020-04-01	2024-07-31	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen mit alpha-2a-adrenergen rezeptor (adra2a) und verfahren zur verwendung davon
AR121769A1 (es)	2020-04-06	2022-07-06	Alnylam Pharmaceuticals Inc	Composiciones y métodos para el silenciamiento de la expresión de myoc
EP4133076A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
CA3179678A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing scn9a expression
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
JP2023522957A (ja)	2020-04-21	2023-06-01	フラッグシップパイオニアリング，インコーポレイテッド	二機能性分子およびその使用方法
KR20230018377A (ko)	2020-04-27	2023-02-07	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
BR112022021136A2 (pt)	2020-04-30	2022-11-29	Alnylam Pharmaceuticals Inc	Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
IL297435A (en)	2020-05-01	2022-12-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating atxn1
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150078A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150090A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
JP2023529903A (ja)	2020-06-09	2023-07-12	アルナイラムファーマシューティカルズ，インコーポレイテッド	ＧＰＡＭ（グリセロール－３－リン酸アシルトランスフェラーゼ１、ミトコンドリア）発現をサイレンシングするためのｓｉＲＮＡ組成物および方法
TW202214856A (zh)	2020-06-18	2022-04-16	美商阿尼拉製藥公司	黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用之方法
CN116390943A (zh)	2020-06-24	2023-07-04	维尔生物科技有限公司	工程化乙型肝炎病毒中和抗体和其用途
KR20230027235A (ko)	2020-06-25	2023-02-27	신톡스, 인크.	Il-2 콘쥬게이트 및 항-egfr 항체를 사용한 면역 종양학 병용 요법
JP7799640B2 (ja)	2020-06-29	2026-01-15	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｐｌｐ１を調節するための化合物及び方法
US12384814B2 (en)	2020-07-28	2025-08-12	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing app expression
PE20231567A1 (es)	2020-08-07	2023-10-04	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular el scn2a
US12329828B2 (en)	2020-09-16	2025-06-17	San Diego State University (Sdsu) Foundation	Pyrimidine nucleoside compounds for fluorescence imaging and spectroscopy
TW202227102A (zh)	2020-09-22	2022-07-16	瑞典商阿斯特捷利康公司	治療脂肪肝病之方法
WO2022066847A1 (en)	2020-09-24	2022-03-31	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
US20230392134A1 (en)	2020-09-30	2023-12-07	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
WO2022076291A1 (en)	2020-10-05	2022-04-14	Alnylam Pharmaceuticals, Inc.	G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
CA3195015A1 (en)	2020-10-09	2022-04-14	Jason MCLELLAN	Prefusion-stabilized hmpv f proteins
CA3194880A1 (en)	2020-10-09	2022-04-14	Carolina E. CAFFARO	Immuno oncology therapies with il-2 conjugates
MX2023004029A (es)	2020-10-09	2023-04-27	Synthorx Inc	Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
CA3198823A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
CA3196205A1 (en)	2020-10-23	2022-04-28	Floyd E. Romesberg	Reverse transcription of polynucleotides comprising unnatural nucleotides
IL302709A (en)	2020-11-13	2023-07-01	Alnylam Pharmaceuticals Inc	Coagulation factor iRNA compositions (F5) and methods of using them
MX2023005736A (es)	2020-11-18	2023-05-25	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular la expresion de angiotensinogeno.
WO2022106695A1 (en)	2020-11-23	2022-05-27	Alpha Anomeric Sas	Nucleic acid duplexes
US11987795B2 (en)	2020-11-24	2024-05-21	The Broad Institute, Inc.	Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
AU2021393417A1 (en)	2020-12-01	2023-06-29	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
EP4259795A1 (de)	2020-12-08	2023-10-18	Alnylam Pharmaceuticals, Inc.	Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
GB2603454A (en)	2020-12-09	2022-08-10	Ucl Business Ltd	Novel therapeutics for the treatment of neurodegenerative disorders
CA3205040A1 (en)	2020-12-18	2022-06-23	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor xii
KR20230135585A (ko)	2020-12-23	2023-09-25	플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨	변형된 trem의 조성물 및 이의 용도
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022174102A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
WO2022174101A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Skin cancer combination therapy with il-2 conjugates and cemiplimab
EP4291654A2 (de)	2021-02-12	2023-12-20	Alnylam Pharmaceuticals, Inc.	Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
JP2024509783A (ja)	2021-02-25	2024-03-05	アルナイラムファーマシューティカルズ，インコーポレイテッド	プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
AU2022226098A1 (en)	2021-02-26	2023-08-24	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL305418A (en)	2021-03-04	2023-10-01	Alnylam Pharmaceuticals Inc	Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4304640A1 (de)	2021-03-12	2024-01-17	Northwestern University	Antivirale impfstoffe mit kugelförmigen nukleinsäuren
MX2023011466A (es)	2021-03-29	2024-02-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de ácido ribonucleico de interferencia (arni) de huntingtina (htt) y métodos de uso de estas.
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
WO2022214632A1 (en)	2021-04-07	2022-10-13	Neoplants Sas	Compositions and methods for indoor air remediation
AU2022262422A1 (en)	2021-04-22	2023-11-02	The Board Of Regents Of The University Of Texas System	All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
TW202309280A (zh)	2021-04-26	2023-03-01	美商艾拉倫製藥股份有限公司	跨膜絲胺酸蛋白酶６（ＴＭＰＲＳＳ６）ｉＲＮＡ組成物及其使用方法
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
JP2024518374A (ja)	2021-05-03	2024-05-01	アルナイラムファーマシューティカルズ，インコーポレイテッド	トランスサイレチン（ｔｔｒ）媒介性アミロイドーシスを治療するための組成物および方法
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
US20240263177A1 (en)	2021-05-20	2024-08-08	Korro Bio, Inc.	Methods and Compositions for Adar-Mediated Editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
EP4347823A1 (de)	2021-06-02	2024-04-10	Alnylam Pharmaceuticals, Inc.	Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
TW202308663A (zh)	2021-06-04	2023-03-01	美商艾拉倫製藥股份有限公司	人類染色體９開讀框７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ劑組成物及其使用方法
EP4351541A2 (de)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4)
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
WO2022258753A1 (en)	2021-06-11	2022-12-15	Bayer Aktiengesellschaft	Type v rna programmable endonuclease systems
KR20240023602A (ko)	2021-06-18	2024-02-22	아이오니스 파마수티컬즈, 인코포레이티드	Ifnar1 발현을 감소시키기 위한 화합물 및 방법
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
US20250034564A1 (en)	2021-06-29	2025-01-30	Korro Bio, Inc.	Methods and Compositions for ADAR-Mediated Editing
AU2022303164A1 (en)	2021-06-30	2024-01-18	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
TW202325312A (zh)	2021-07-23	2023-07-01	美商艾拉倫製藥股份有限公司	β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法
EP4377458A1 (de)	2021-07-29	2024-06-05	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa-reduktase (hmgcr)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3227852A1 (en)	2021-08-03	2023-02-09	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof
AU2022324003A1 (en)	2021-08-04	2024-02-08	Alnylam Pharmaceuticals, Inc.	iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
MX2024001573A (es)	2021-08-13	2024-02-14	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) contra el factor xii (f12) y sus metodos de uso.
JP2024538859A (ja)	2021-08-31	2024-10-24	アルナイラムファーマシューティカルズ，インコーポレイテッド	細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法
EP4396352A4 (de)	2021-09-01	2025-10-01	Ionis Pharmaceuticals Inc	Verbindungen und verfahren zur reduzierung der dmpk-expression
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
JP2024535888A (ja)	2021-09-20	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法
MX2024003519A (es)	2021-09-24	2024-04-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
AU2022356427A1 (en)	2021-09-30	2024-05-09	Akouos, Inc.	Compositions and methods for treating kcnq4-associated hearing loss
IL311518A (en)	2021-10-01	2024-05-01	Adarx Pharmaceuticals Inc	Preparations that modulate perkalkerine and methods of using them
WO2023069603A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
JP2024541974A (ja)	2021-10-29	2024-11-13	アルナイラムファーマシューティカルズ，インコーポレイテッド	ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
CA3237769A1 (en)	2021-11-10	2023-05-19	University Of Rochester	Gata4-targeted therapeutics for treatment of cardiac hypertrophy
WO2023086295A2 (en)	2021-11-10	2023-05-19	University Of Rochester	Antisense oligonucleotides for modifying protein expression
GB202117758D0 (en)	2021-12-09	2022-01-26	Ucl Business Ltd	Therapeutics for the treatment of neurodegenerative disorders
EP4452327A1 (de)	2021-12-20	2024-10-30	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
WO2023118349A1 (en)	2021-12-21	2023-06-29	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
EP4453191A1 (de)	2021-12-23	2024-10-30	Bayer Aktiengesellschaft	Neuartige programmierbare endonukleasesysteme für kleine v-rna
EP4469575A2 (de)	2022-01-24	2024-12-04	Alnylam Pharmaceuticals, Inc.	Enzym-irna-wirkstoffzusammensetzungen für den heparinsulfatbiosyntheseweg und verfahren zur verwendung davon
JP2025507751A (ja)	2022-03-01	2025-03-21	クリスパー・セラピューティクス・アクチェンゲゼルシャフト	アンジオポエチン様３（ａｎｇｐｔｌ３）関連状態を処置するための方法および組成物
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
EP4536818A1 (de)	2022-06-10	2025-04-16	Bayer Aktiengesellschaft	Neuartige programmierbare endonukleasesysteme für kleine v-rna
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
EP4581143A1 (de)	2022-08-29	2025-07-09	University of Rochester	Anti-fibrotische therapeutika auf der basis von antisense-oligonukleotiden
EP4569113A1 (de)	2022-09-15	2025-06-18	Regeneron Pharmaceuticals, Inc.	17b-hydroxysteroiddehydrogenase-typ-13 (hsd17b13)-irna-zusammensetzungen und verfahren zu ihrer verwendung
EP4587564A2 (de)	2022-09-16	2025-07-23	Alia Therapeutics Srl	Enqp-typ-ii-cas-proteine und anwendungen davon
US12152052B2 (en)	2022-09-23	2024-11-26	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing MECP2 expression
EP4619535A1 (de)	2022-11-16	2025-09-24	Alia Therapeutics Srl	Typ-ii-cas-proteine und anwendungen davon
EP4634376A2 (de)	2022-12-13	2025-10-22	Bayer Aktiengesellschaft	Gentechnisch hergestellte typ-v-rna-programmierbare endonukleasen und deren verwendungen
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024151586A2 (en)	2023-01-09	2024-07-18	Board Of Regents, The University Of Texas System	Prefusion-stabilized human parainfluenza virus 3 f proteins
JP2026502531A (ja)	2023-01-11	2026-01-23	アリアセラピューティクスエスアールエル	Ｉｉ型ｃａｓタンパク質およびその適用
EP4662311A2 (de)	2023-02-09	2025-12-17	Alnylam Pharmaceuticals, Inc.	Reversirmoleküle und verfahren zu ihrer verwendung
EP4665865A1 (de)	2023-02-17	2025-12-24	Anjarium Biosciences AG	Verfahren zur herstellung von dna-molekülen und zusammensetzungen und verwendungen davon
WO2024196937A1 (en)	2023-03-20	2024-09-26	Synthorx, Inc.	Cancer therapy with il-2 peg conjugates
WO2024197242A1 (en)	2023-03-23	2024-09-26	Carbon Biosciences, Inc.	Protoparvovirus compositions comprising a protoparvovirus variant vp1 capsid polypeptide and related methods
EP4683931A1 (de)	2023-03-23	2026-01-28	Carbon Biosciences, Inc.	Parvoviruszusammensetzungen und zugehörige verfahren zur gentherapie
TW202444908A (zh)	2023-04-06	2024-11-16	大陸商上海舶望製藥有限公司	５＇－膦酸酯修飾的核苷類似物及其製備的寡核苷酸
EP4698652A2 (de)	2023-04-20	2026-02-25	Adarx Pharmaceuticals, Inc.	Mapt-modulierende zusammensetzungen und verfahren zur verwendung davon
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
KR20260021635A (ko)	2023-05-12	2026-02-13	아다르엑스 파마슈티컬스, 인크.	Nmda 리간드 접합 화합물 및 이의 용도
WO2024243062A1 (en)	2023-05-19	2024-11-28	Streck Llc	Detection of antibiotic resistance genes
CN121335980A (zh)	2023-05-26	2026-01-13	阿达尔克斯制药有限公司	Sod1调节组合物及其使用方法
TW202506137A (zh)	2023-06-20	2025-02-16	美商雅迪克斯製藥公司	Ｌｒｒｋ２調節組合物及其使用方法
WO2025003344A1 (en)	2023-06-28	2025-01-02	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025015338A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en)	2023-07-21	2026-01-22	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
AU2024299627A1 (en)	2023-07-25	2026-01-22	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
US20250092375A1 (en)	2023-07-25	2025-03-20	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
WO2025034422A1 (en)	2023-08-04	2025-02-13	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating ctnnb1-associated disorders
US20250243487A1 (en)	2023-09-14	2025-07-31	Ionis Pharmaceuticals, Inc.	Compounds and Methods for Reducing APOCIII Expression
WO2025064821A2 (en)	2023-09-21	2025-03-27	Ionis Pharmaceuticals, Inc.	Compounds and methods for inhibiting lpa
WO2025072331A1 (en)	2023-09-26	2025-04-03	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
GB202314724D0 (en)	2023-09-26	2023-11-08	Astrazeneca Ab	compounds and methods for reducing psd3 expression
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
WO2025072699A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
TW202521691A (zh)	2023-10-06	2025-06-01	美商藍岩醫療公司	經工程化之v型rna可程式核酸內切酶及其用途
AU2024369609A1 (en)	2023-10-31	2025-12-11	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025117877A2 (en)	2023-12-01	2025-06-05	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025165891A1 (en)	2024-01-29	2025-08-07	Arnatar Therapeutics, Inc	Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
EP4671372A3 (de)	2024-01-29	2026-03-11	Arnatar Therapeutics, Inc	Translationsverstärkende nukleinsäureverbindungen: aso-gekoppelte translation - hochregulierung 1 (act-up1) und verwendungen davon
TW202543656A (zh)	2024-02-19	2025-11-16	美商旗艦先鋒創新有限責任（Ｖｉｉ）公司	靶向ＣＩＤＥＢ之ＲＮＡｉ藥劑及相關方法
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
GB202404290D0 (en)	2024-03-26	2024-05-08	Senisca Ltd	Novel oligoncleotides
WO2025210147A1 (en)	2024-04-04	2025-10-09	Alia Therapeutics Srl	Type v cas proteins and applications thereof
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1046044A (en) *	1964-02-24	1966-10-19	Shionogi & Co	Pyrimidopyrimidothiazine compounds and/or thiazine compounds and production thereof
US3583298A (en) *	1967-02-07	1971-06-08	Earl C Van Swearingen	Color picture reproduction
US3706748A (en) *	1971-10-04	1972-12-19	Daniel D Rosenfeld	Substituted uracil phosphates as pesticides
AT346361B (de) *	1976-05-28	1978-11-10	Hoffmann La Roche	Verfahren zur herstellung des neuen 1- (2,3- dihydro-2-furyl)-5-fluoruracils
US4396623A (en) *	1981-08-26	1983-08-02	Southern Research Institute	Carbocyclic analogs of uracil nucleosides as antiviral agents
US5047533A (en) *	1983-05-24	1991-09-10	Sri International	Acyclic purine phosphonate nucleotide analogs
DK167280B1 (da) *	1985-03-20	1993-10-04	Ciba Geigy Ag	3-aryluracilderivater, fremgangsmaade til fremstilling deraf, ukrudtsbekaempelsesmidler indeholdende disse derivater samt anvendelsen af derivaterne til ukrudtsbekaempelse
JPS6259293A (ja) *	1985-09-09	1987-03-14	Teijin Ltd	螢光性ヌクレオシド又はヌクレオチド
CS264222B1 (en) *	1986-07-18	1989-06-13	Holy Antonin	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
NL8700724A (nl) *	1987-03-27	1988-10-17	Univ Eindhoven Tech	Poly(deoxyribonucleotiden), farmaceutische samenstellingen, gebruik en bereiding van de poly(deoxyribonucleotiden).
US5030557A (en) *	1987-11-24	1991-07-09	Ml Technology Venture	Means and method for enhancing nucleic acid hybridization
SE8802173D0 (sv) *	1988-06-10	1988-06-10	Astra Ab	Pyrimidine derivatives
US5130238A (en) *	1988-06-24	1992-07-14	Cangene Corporation	Enhanced nucleic acid amplification process
US4879214A (en) *	1988-11-15	1989-11-07	E. I. Du Pont De Nemours And Company	Differentiation of nucleic acid segments on the basis of nucleotide differences
US5145960A (en) *	1989-04-24	1992-09-08	E. R. Squibb & Sons, Inc.	Pyrimidinyl tetrahydrofurans
US5106727A (en) *	1989-04-27	1992-04-21	Life Technologies, Inc.	Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers
US5043272A (en) *	1989-04-27	1991-08-27	Life Technologies, Incorporated	Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers
US5049551A (en) *	1989-05-30	1991-09-17	Ube Industries, Ltd.	5-fluorouracil, 2'-deoxy-5-fluorouridine and 1-carbomoyl-5-fluorouracil compounds
US5112736A (en) *	1989-06-14	1992-05-12	University Of Utah	Dna sequencing using fluorescence background electroblotting membrane
US5232830A (en) *	1990-05-11	1993-08-03	Microprobe Corporation	Intrinsic fluorescent quenching methods
DE4015715A1 (de) *	1990-05-16	1991-11-21	Bayer Ag	Neuartige oligophosphate mit antiviraler wirkung
US5194370A (en) *	1990-05-16	1993-03-16	Life Technologies, Inc.	Promoter ligation activated transcription amplification of nucleic acid sequences
CS276072B6 (en) *	1990-08-06	1992-03-18	Ustav Organicke Chemie A Bioch	(2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF
DE4035479A1 (de) *	1990-11-08	1992-05-14	Basf Ag	Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
US5208221A (en) *	1990-11-29	1993-05-04	Bristol-Myers Squibb Company	Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
US5169766A (en) *	1991-06-14	1992-12-08	Life Technologies, Inc.	Amplification of nucleic acid molecules
ATE169342T1 (de) *	1991-09-19	1998-08-15	Vysis Inc	Sondezusammensetzungen fuer genomanalyse und methoden
PH31245A (en) *	1991-10-30	1998-06-18	Janssen Pharmaceutica Nv	1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
AU6632094A (en) *	1993-04-19	1994-11-08	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5502177A (en) *	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners

1993
- 1993-09-17 US US08/123,505 patent/US5502177A/en not_active Expired - Lifetime
1994
- 1994-09-16 DE DE69432636T patent/DE69432636T2/de not_active Expired - Lifetime
- 1994-09-16 EP EP94929830A patent/EP0719272B1/de not_active Expired - Lifetime
- 1994-09-16 JP JP50939395A patent/JP4098356B2/ja not_active Expired - Lifetime
- 1994-09-16 WO PCT/US1994/010536 patent/WO1995007918A2/en not_active Ceased
- 1994-09-16 AT AT94929830T patent/ATE239752T1/de not_active IP Right Cessation
1995
- 1995-05-08 US US08/436,991 patent/US6005096A/en not_active Expired - Lifetime
- 1995-06-07 US US08/481,719 patent/US5763588A/en not_active Expired - Lifetime
1999
- 1999-12-21 US US09/468,454 patent/US6617437B1/en not_active Expired - Fee Related
2002
- 2002-11-14 US US10/294,066 patent/US6967079B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69432636T2 (de)	2004-03-25
EP0719272A1 (de)	1996-07-03
US20030207824A1 (en)	2003-11-06
WO1995007918A3 (en)	1995-08-03
US6617437B1 (en)	2003-09-09
US5502177A (en)	1996-03-26
US6005096A (en)	1999-12-21
EP0719272B1 (de)	2003-05-07
DE69432636D1 (de)	2003-06-12
US6967079B2 (en)	2005-11-22
JP4098356B2 (ja)	2008-06-11
JPH09506859A (ja)	1997-07-08
WO1995007918A2 (en)	1995-03-23
US5763588A (en)	1998-06-09

Legal Events

Date	Code	Title	Description
2003-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE239752T1 (de)	2003-05-15	Pyrimidinderivate als markierte bindungspartner
SE8004783L (sv)	1981-02-26	Delta?722-1,2,4triazolin-5-on-derivat
DK0594291T3 (da)	2003-01-27	Fremgangsmåder til fremstilling af 13-etherderivater af milbemyciner og mellemprodukter dertil
AU654212B2 (en)	1994-10-27	Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use
MY108659A (en)	1996-10-31	Pesticidal 1-(2-pyridyl) pyrazoles
DK379986D0 (da)	1986-08-08	Flydende vandigt praeparat af en 2-amino-5-oxo-5h-(1)-benzopyran(2,3-b)-pyridin-3-karboxylsyre
IE883845L (en)	1989-06-23	Adenosine derivative
UA27220C2 (uk)	2000-08-15	Спосіб одержання похідних 1-фенілімідазолін-2,5-діону
DK0532515T3 (da)	1997-04-21	Fremstilling af substituerede piperidiner
MX9203331A (es)	1992-12-01	Derivados de pirimidina-4-carboxamida, su preparacion y su aplicacion en terapeutica.
ES445790A1 (es)	1977-06-01	Procedimiento para preparar derivados de 3-formilrifamicina sv.
YU171190A (sh)	1992-07-20	Postupak za dobijanje 23-(c1-c6 alkiloksim) makrolidnih jedinjenja
DK0619806T3 (da)	1996-02-05	Fremstilling af substituerede piperidiner
IE780431L (en)	1978-09-04	Imidazole 4, 5-dicarboxamides; herbicides
IE811580L (en)	1982-01-16	Herbicidal compounds
EP0712398A1 (de)	1996-05-22	Benzopyrane und diese enthaltende pharmazeutische zusammenstellungen
EP0383318A3 (de)	1991-04-17	Aralkylamin-Verbindungen
EP0598910A4 (de)	1994-02-07	Verfahren zur herstellung von nukleosidderivaten.
FI820240L (fi)	1982-07-30	Nytt framstaellningsfoerfarande foer 17alfa-hydroxi-17beta-hydroxiacetylsteroider och pao motsvarande saett erhaollna mellanprodukter
SE8004621L (sv)	1980-12-26	Bensimidazolderivat
ES471534A1 (es)	1979-01-16	Proceso para la produccion de derivados de la tunicamina
AU7032594A (en)	1995-04-06	Azoxycyanobenzene derivatives
ATE258187T1 (de)	2004-02-15	Herstellung von 2'-substitutierter rns
ES483557A1 (es)	1980-04-16	Procedimiento para la preparacion de derivados de imidazol
KR970042501A (ko)	1997-07-24	새로운 아민고리 화합물